Type of information: Co-promotion agreement
Compound: Dysport® (abobotulinumtoxin A )
Company: Ipsen (France) Saol Therapeutics (USA - GA)
Therapeutic area: Neurological diseases - Neuromuscular diseases
Type agreement: co-promotion
Action mechanism: protein. Dysport® is an injectable form of botulinum toxin type A (BTX-A), which is isolated and purified from Clostridium BTX-A bacteria. It is supplied as a lyophilized powder. Dysport® was first registered for the treatment of blepharospasm and hemifacial spasm in the United Kingdom in 1990, and is licensed in 82 countries for various indications including: blepharospasm, adult upper and lower limb spasticity, hemifacial spasm, spasmodic torticollis (ST) (previously referred to as cervical dystonia), pediatric lower limb spasticity due to cerebral palsy (CP), axillary hyperhidrosis, and glabellar lines. Dysport® is approved for the treatment of upper limb spasticity and pediatric lower limb spasticity in many international markets, but not in the United States. Dysport® is also approved for the treatment of adult lower limb spasticity.
Disease: adult spasticity, pediatric lower limb spasticity